A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants
Completed · Phase 1 · NCT06887010
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $9,838
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 17
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-101 (drug)
- Dates
- Started 2025-03-25; completion 2025-09-16
- Results posted
- Not yet
This study will assess the effect of food (high fat) on oral ABBV-101 and how ABBV-101 moves through the body in healthy adult participants
From ClinicalTrials.gov, last updated 2025-10-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $9,838 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $9,838
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.